David Kirn, 4D Molecular Therapeutics CEO

Astel­las eyes rare oph­thal­mol­o­gy, li­cens­ing 4DMT's vi­ral vec­tor for gene ther­a­py for up to $962M

Astel­las will pay 4D Mol­e­c­u­lar Ther­a­peu­tics $20 mil­lion up­front to use its vi­ral vec­tor for a rare mono­genic eye dis­ease in a deal worth up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.